Med BioGene has named Melanie Mahtani as executive advisor of commercial development. Mahtani formerly was vice president of business development for Genospectra; director of microarray systems at Amersham Biosciences; vice president of corporate business development at Panomics; and a fellow at the Whitehead Institute for Biomedical Research.
Jeremy Levin, Elliott Sigal, Governor Martin O’Malley, Melanie Mahtani
Bristol-Myers Squibb announced last week that Jeremy Levin has joined the company as senior vice president of external science, technology, and licensing.
Levin will report to Elliott Sigal, chief scientific officer and president of R&D. Levin previously served as global head of business development and strategic alliances at the Novartis Institutes of Biomedical Research. Prior to that, Levin hald leadership positions at several biotech firms, including Physiome Sciences and Cadus Pharmaceutical, BMS said. He was also managing director of Perseus Capital, a life sciences venture fund. Levin holds a PhD in cell biology and chromatin structure from the University of Oxford, and an MD from the University of Cambridge.
Maryland Governor Martin O’Malley has appointed Venable partner Charles Morton to the board of directors of the Maryland Technology Development Corporation.
Morton is the only attorney on Tedco’s current 15-member board, the organization said. Morton’s practice focuses on representing entrepreneurs and investors in entrepreneurial start-up firms. He is the current president of the Maryland Chapter of the Association of Corporate Growth, and teaches an undergraduate course on technology transfer at Johns Hopkins University.